What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 4 months ago
EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/BjvUm0wPNk https://t.co/IVisAgD1wZ
Dr. John Cush RheumNow
3 years 4 months ago
BSRBR mandates LFTs q3 mos if on MTX. 1011 RA pts during the pandemic had median of 5 blood tests & median interval of 57 days. 61% pts had 1 prolonged interval (99-150d) & 24% had multiple. Cytopenia & ^LFTs were not increased by interval length https://t.co/VqY4qIMvOS https://t.co/HcTcmFBuvq
Dr. John Cush RheumNow
3 years 4 months ago
210 consecutive #RA pts starting #MTX looked at effect of autoantibodies on drug response. DAS28-CRP low dz activity at 6 mos was significantly lower with SSA+ (56% v 76%, P=0.03) - which was more significant than CCP+ or RF+ https://t.co/DoEtldBXi4
Figures https://t.co/yIECjLiEwl
The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list released yesterday.
Dr. John Cush RheumNow
3 years 4 months ago
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders.
https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz
Eric Topol EricTopol
3 years 4 months ago
Every moderately to severely immunocompromised person should know about Evusheld, a preventive Rx. It's uncommonly prescribed by doctors and there's a general lack of awareness. Still works vs BA.5
An excellent patient page @JAMA_current https://t.co/Exn82D8712 @AnuMalaniMD https://t.co/Rpdhcgg33h
Management of arthralgias before a certified rheumatoid arthritis (RA) diagnosis is challenging - should one use DMARD therapy before clinically evident synovitis in a preemptive effort to avoid or forestall the diagnosis or damage of RA?
Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.
Dr. John Cush RheumNow
3 years 4 months ago
Risk of hospitalized infection (SIE) goes up with #RA disease activity. Study of 3,254 RA Pts with 529 SIE - SIE rates lowest with remission (3.8/100PY), vs low dz activity (6.6/100PY; OR 1.60) vs moderate activity (8.8/100PY; OR 183) https://t.co/EWbX7N7fiG https://t.co/Y8bRn2XATF
Dr. John Cush RheumNow
3 years 4 months ago
New download available on the diagnosis & treatment of Still's Disease.
Register on RheumNow and download for immediate use.
https://t.co/YvgsEtVHVc https://t.co/N9K0cjfakC
Dr. John Cush RheumNow
3 years 4 months ago
Tonight! Sign up for Tuesday Night Rheumatology at 7pm!
https://t.co/bnEXGUeeyx https://t.co/A4MaXWfhRO
Dr. John Cush RheumNow
3 years 4 months ago
Transcription factor ETS-related gene (ERG) is an orchestrator of lung capillary homeostasis & repair. Dysfunctional ERG signaling drives pulmonary vascular aging and persistent fibrosis https://t.co/TMFBa74ob7 https://t.co/n60DwGaa74
Dr. John Cush RheumNow
3 years 4 months ago
Heterozygous deficiency of Aggrecan (proteoglycan w/in cartilage) gene: manifests as inherited short stature, early-onset osteoarthritis, degenerative disc disease, osteochondritis dissecans, increasing joint pathology over time https://t.co/4iQdNL79oB https://t.co/qxStgE641v https://t.co/EHPJuIeQGt
Poster Hall